Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Courtyard by Marriott Brussels

Sep 25, 2023 12:30 PM - Sep 26, 2023 6:00 PM

Av. des Olympiades 6, 1140 Brussels, Belgium

DIA Health Technology Assessment (HTA) Forum

Creating a successful European HTA system to accelerate patient's access

Session 2: What Does EU HTA Mean for Global Clinical Development Plans and Evidence Generation?

Session Chair(s)

Claudine  Sapède, PharmD

Claudine Sapède, PharmD

Director, Global HTA Policy

NOVARTIS INTERNATIONAL, Switzerland

Matias  Olsen, MA

Matias Olsen, MA

Senior Manager, Public Affairs & Policy

European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Belgium

Joint scientific consultation (JSC) provides an opportunity for companies to develop plans for the generation of evidence that can meet the needs of both regulatory agency and HTA bodies and facilitate the preparation of joint clinical assessments. Yet, proposing an asset for JSC presents both opportunities & challenges. In this session, we will discuss how cross-functional collaboration across access, regulatory, clinical development and other functions can help optimizing clinical development plans and evidence generation in the context of EU HTA.

Speaker(s)

Martin  Scott

Scene Setting

Martin Scott

Numerus GmbH, Germany

Scientific Director

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.